Pure Global
NCT05793450

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Renal Impairment
Drug/Device/Intervention
IBI362
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
May 05, 2023
End date
Oct 13, 2023
Enrollment
24 participants
Primary outcome

Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362,PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362

Summary

The purpose of this study is to assess how fast IBI362 gets into the blood stream and how
 long it takes the body to remove it in participants with impaired kidney function compared to
 healthy participants.

ICD-10 classifications
Renal failureDisorders resulting from impaired renal tubular functionDisorder resulting from impaired renal tubular function, unspecifiedOther disorders resulting from impaired renal tubular functionAcute renal failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05793450
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05793450 through Pure Global AI's free database. This Phase 1 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Recruiting. The study focuses on Renal Impairment. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.